AOD-9604 vs. Lixisenatide

Category

Growth

Metabolic

CAS no.

221231-10-3

320367-13-3

Molecular weight

1815.09 g/mol

4858.5 g/mol

Half-life

0.4 h

3 h

Sequence

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Highest evidence

Studies

3

5

of which in humans

2

5

Effects recorded

3

3

Open conflicts

1

1

Documented adverse events

1

1